Videregen raises £3.1m

The fresh capital will be used to enable extensive manufacturing development and clinical research as the company aims to create the world's first commercially available tissue-engineered stem cell organ replacement product.

Company
Videregen is a research institute spinout based in Liverpool Science Park. The company's approach begins by removing cells from a windpipe, which has been removed posthumously from a donor. The patient's stem cells are then seeded into the windpipe to multiply and create a living organ in a controlled laboratory to then be transplanted. This technique dramatically reduces the chances of the organ being rejected.

Videregen's first product from its platform technology has been windpipe replacement and it will look to develop bowel and liver replacement organs in partnership with Northwick Park Institute for Medical Research.

The company also works with the NHS Blood and Transplant centre in Speke and in collaboration with University College London, the Cell Therapy Catapult and the Royal Free hospital in London.

People
Dr Steve Bloor is CEO of Videregen. Dr Marc d'Abbadie is investment director at Spark.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• UK / Ireland
• Early-stage
• SPARK Ventures
• United Kingdom